We are live on
!
Find out more
Los Angeles Capital Management Portfolio holdings
AUM
$25.4B
1-Year Est. Return
38.46%
This Fund
S&P 500
This Quarter
Est. Return
-3.12%
1 Year Est. Return
+38.46%
3 Year Est. Return
+154.38%
5 Year Est. Return
+223.79%
10 Year Est. Return
+923.25%
AUM
$19.3B
AUM Growth
-$1.05B
(-5.2%)
Cap. Flow
-$77.1M
Cap. Flow
% of AUM
-0.4%
Top 10 Holdings %
Top 10 Hldgs %
26.03%
Holding
1,444
New
138
Increased
405
Reduced
531
Closed
234
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$224M |
| 2 |
Brown-Forman Class B
BF.B
|
+$140M |
| 3 |
UnitedHealth
UNH
|
+$132M |
| 4 |
Monolithic Power Systems
MPWR
|
+$108M |
| 5 |
Oracle
ORCL
|
+$97.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class C
GOOG
|
+$134M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$122M |
| 3 |
Micron Technology
MU
|
+$122M |
| 4 |
Pfizer
PFE
|
+$120M |
| 5 |
Microsoft
MSFT
|
+$117M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.43% |
| 2 | Healthcare | 14.49% |
| 3 | Financials | 11.62% |
| 4 | Consumer Discretionary | 10.92% |
| 5 | Industrials | 8.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
301
Newmont
NEM
$124B
| $8.03M | 0.04% |
191,015
+185,461
| +3,339% | +$8.66M |
|
302
EPR Properties
EPR
$4.7B
| $7.9M | 0.04% |
220,420
+169,277
| +331% | +$7.99M |
|
303
Genuine Parts
GPC
$18.5B
| $7.88M | 0.04% |
52,788
+21,545
| +69% | +$3.25M |
|
304
Kraft Heinz
KHC
$29.1B
| $7.82M | 0.04% |
234,379
-717,463
| -75% | -$26.7M |
|
|
WRK
305
DELISTED
WestRock Company
WRK
| $7.72M | 0.04% |
249,790
-158,735
| -39% | -$6.27M |
|
306
NIO
NIO
$11.4B
| $7.46M | 0.04% |
473,020
-173,323
| -27% | -$3.43M |
|
|
SNV
307
DELISTED
Synovus
SNV
| $7.46M | 0.04% |
198,741
+51,034
| +35% | +$2.02M |
|
|
BKI
308
DELISTED
Black Knight, Inc. Common Stock
BKI
| $7.44M | 0.04% |
+114,893
| New | +$7.57M |
|
309
Halozyme
HALO
$11.6B
| $7.16M | 0.04% |
181,153
-14,460
| -7% | -$639K |
|
310
CME Group
CME
$94.3B
| $7.16M | 0.04% |
40,399
-11,860
| -23% | -$2.34M |
|
311
XPeng
XPEV
$11.2B
| $7.15M | 0.04% |
598,182
-78,152
| -12% | -$1.68M |
|
312
Expedia Group
EXPE
$39.1B
| $7.1M | 0.04% |
75,773
+7,898
| +12% | +$806K |
|
313
Encompass Health
EHC
$12.3B
| $7.06M | 0.04% |
156,042
-105,443
| -40% | -$5.28M |
|
314
DoubleVerify
DV
$2.04B
| $7.05M | 0.04% |
+257,733
| New | +$6.65M |
|
315
Repligen
RGEN
$9.35B
| $7.03M | 0.04% |
37,569
-26,387
| -41% | -$5.56M |
|
|
SF
316
Stifel
SF
$12.8B
| $6.91M | 0.04% |
199,761
-188,948
| -49% | -$7.44M |
|
317
Royalty Pharma
RPRX
$26.4B
| $6.76M | 0.04% |
168,173
-85,093
| -34% | -$3.63M |
|
318
Alliant Energy
LNT
$18.2B
| $6.75M | 0.04% |
+127,425
| New | +$7.69M |
|
319
Honeywell
HON
$74.6B
| $6.75M | 0.04% |
42,872
+1,368
| +3% | +$238K |
|
320
Prosperity Bancshares
PB
$8.95B
| $6.72M | 0.03% |
100,833
+77,186
| +326% | +$5.51M |
|
321
Thermo Fisher Scientific
TMO
$223B
| $6.66M | 0.03% |
13,135
-44,171
| -77% | -$24.7M |
|
322
Colgate-Palmolive
CL
$73.6B
| $6.52M | 0.03% |
92,862
+1,880
| +2% | +$147K |
|
323
Qualys
QLYS
$6.47B
| $6.46M | 0.03% |
46,371
+30,258
| +188% | +$4.26M |
|
324
First American
FAF
$7.38B
| $6.44M | 0.03% |
139,717
-3,904
| -3% | -$211K |
|
325
M&T Bank
MTB
$36.6B
| $6.44M | 0.03% |
36,510
+495
| +1% | +$87.6K |
|
Similar funds
VAI
Los Angeles Capital Management's Q3 2022 Portfolio in Review
As of Q3 2022, Los Angeles Capital Management held 1,444 positions worth $19.3B, down 5.2% from $20.3B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Los Angeles Capital Management's Q3 2022 filing shows 138 new, 405 increased, 531 reduced and 234 closed positions. Its largest new stake was Neurocrine Biosciences: 791,966 shares worth $84.1M. The largest sale was Alphabet (Google) Class C, an estimated $134M.
By sector, the portfolio is most concentrated in Technology at 31% of assets, down from 32% a quarter earlier, followed by Healthcare and Financials.
- Los Angeles Capital Management's largest Q3 2022 buy was Neurocrine Biosciences: 791,966 shares worth $84.1M.
- Los Angeles Capital Management added most to Broadcom in Q3 2022, an estimated $224M increase.
- Los Angeles Capital Management's biggest Q3 2022 reduction was Alphabet (Google) Class C, cutting an estimated $134M.
- Los Angeles Capital Management fully exited D.R. Horton in Q3 2022, selling an estimated $37.1M.
- Los Angeles Capital Management's ten largest holdings make up 26% of its $19.3B portfolio in Q3 2022.
- Los Angeles Capital Management opened 138 new positions and closed 234 in Q3 2022.
- Los Angeles Capital Management's portfolio value fell 5.2% quarter-over-quarter to $19.3B.
Based on Los Angeles Capital Management's 13F filing for Q3 2022, filed 2 Nov 2022.